Golden Meditech’s $830 Million Sale of Stake in China Cord Blood

Shearman & Sterling is advising Hong Kong-listed Golden Meditech, a leading integrated healthcare company engaged in the development, manufacture, sales and distribution of blood-related medical devices and hospital management in China, on the sale of its stake in China Cord Blood for US$830 million.

The transaction is expected to complete by the first quarter of 2017.

Listed on the New York Stock Exchange, China Cord Blood is a leading provider of cord blood processing and storage services and is also the largest cord blood banking operator in China.

Golden Meditech Holdings Ltd, through its subsidiaries, develops, manufactures, and sells blood recovery machines (ABRS Machines), Portable ABMR Machines, and disposable blood processing chambers and related accessories. The company, led by Kam Yuen, Kwok Kuen Yu, Shao Bao Ping,

Zhang Jin Feng and Huang Fan, is based in

Hong Kong.

The Shearman & Sterling team included partner Paul Strecker (Picture) (London/Hong Kong-Mergers & Acquisitions); and associates Richard Ou (Hong Kong-Mergers & Acquisitions), Shan Wu and Weina Guan (both Beijing-Mergers & Acquisitions).

Involved fees earner: Paul Strecker – Shearman & Sterling; Richard Ou – Shearman & Sterling; Shan Wu – Shearman & Sterling; Weina Guan – Shearman & Sterling;

Law Firms: Shearman & Sterling;

Clients: Golden Meditech Holdings Ltd;


Author: Michael Patrini